- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
LIXTE Biotechnology Files 2025 Annual Report
Pharmaceutical company highlights transformative year in regulatory filings.
Mar. 31, 2026 at 10:30pm
Got story updates? Submit your updates here. ›
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, has filed its 2025 annual report on Form 10-K, providing an overview of the company's operational highlights and progress over the past year.
Why it matters
As a publicly traded biotech firm, LIXTE's annual report offers investors and the broader industry insights into the company's drug development pipeline, financial performance, and strategic direction - all of which are crucial for understanding the state of the pharmaceutical sector.
The details
In the 2025 filing, LIXTE detailed advancements across its clinical programs, including the initiation of late-stage trials for its lead drug candidate and the expansion of its research into new therapeutic areas. The report also covered the company's financial results, capital raises, and key organizational changes over the past fiscal year.
- LIXTE filed its 2025 annual report on Form 10-K on March 31, 2026.
The players
LIXTE Biotechnology Holdings, Inc.
A clinical-stage pharmaceutical company focused on developing innovative cancer therapies and other therapeutic areas.
The takeaway
LIXTE's 2025 annual report highlights the company's progress in advancing its drug pipeline and navigating the complex regulatory landscape of the pharmaceutical industry, signaling its continued growth and potential to deliver new treatments to patients.
